Skip to main content
. 2019 Sep 18;10:861. doi: 10.3389/fgene.2019.00861

Table 2.

DNA damage response inhibitors in clinical development.

Target Compound
BER
PARP Olaparib
Rucaparib
Niraparib
Talazoparib
Veliparib
APE1 Methoxyamine
HRR
ATR VX-970
AZD6738
NHEJ
DNA-PKcs MSC2490484A
CC-115
Checkpoint inhibitors
CHK1 GDC-0575
MK-8776
CHK1 and CHK2 LY2606368
PF-00477736
ATM AZD0156
WEE1 AZD11775